Jasper Therapeutics (JSPR) Net Equity Issued and Repurchased (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Net Equity Issued and Repurchased of $514000.0 for Q3 2025, down 98.91% quarter-over-quarter from $47.2 million in Q1 2024.
Jasper Therapeutics (JSPR) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $514000.0 for Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $514000.0; the TTM figure through Dec 2025 stood at $514000.0 (down 98.91% YoY), while the FY2025 annual figure was $6.5 million, down 86.32% from the prior year.
- Net Equity Issued and Repurchased for Q3 2025 stood at $514000.0, down from $47.2 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $101.5 million in Q1 2023, with the low at $514000.0 in Q3 2025.
- The 4-year median for Net Equity Issued and Repurchased is $29.0 million (2021), against an average of $40.0 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 53.49% in 2024, while the deepest fall reached 53.49% in 2024.
- Jasper Therapeutics' Net Equity Issued and Repurchased stood at $10.8 million in 2021, then soared by 843.99% to $101.5 million in 2023, then slumped by 53.49% to $47.2 million in 2024, then tumbled by 98.91% to $514000.0 in 2025.
- Business Quant data shows JSPR's Net Equity Issued and Repurchased at $514000.0 in Q3 2025, $47.2 million in Q1 2024, and $101.5 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 514,000.00 |
| Sep 30, 2025 | 514,000.00 |
| Mar 31, 2024 | 47.20 Mn |
| Mar 31, 2024 | 47.20 Mn |
| Mar 31, 2023 | 101.48 Mn |
| Mar 31, 2023 | 101.48 Mn |
| Mar 31, 2021 | 10.75 Mn |
| Mar 31, 2021 | 10.75 Mn |
| Dec 31, 2020 | 10.75 Mn |
| Dec 31, 2020 | 10.75 Mn |